分化型甲状腺癌术后<sup>131</sup>I清甲治疗方法的相关问题

李敬彦; 蒋宁一; 李敬彦; 蒋宁一

doi:10.3760/cma.j.issn.1673-4114.2014.01.009

[1]

中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, 等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华内分泌代谢杂志, 2012, 28(10):779-797. doi: 10.3760/cma.j.issn.1000-6699.2012.10.002

[2]

Molinaro E, Viola D, Passannanti P, et al. Recombinant human TSH(rhTSH) in 2009:new perspectives in diagnosis and therapy[J]. Q J Nucl Med Mol Imaging, 2009, 53(5):490-502.

[3]

Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi ¹³¹I:a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal[J]. J Clin Endocrinol Metab, 2002, 87(9):4063-4068. doi: 10.1210/jc.2001-011918

[4]

Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma:results of an international, randomized, controlled study[J]. J Clin Endocrinol Metab, 2006, 91(3):926-932. doi: 10.1210/jc.2005-1651

[5]

Schlumberger M, Ricard M, De Pouvourville G, et al. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer[J]. Nat Clin Pract Endocrinol Metab, 2007, 3(9):641-650. doi: 10.1038/ncpendmet0594

[6]

Hänscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer:procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal[J]. J Nucl Med, 2006, 47(4):648-654.

[7]

关海霞, 陆汉魁.重组人促甲状腺激素在甲状腺疾病诊治中的应用[J].中华核医学与分子影像杂志, 2012, 32(4):311-314. doi: 10.3760/cma.j.issn.2095-2848.2012.04.023

[8]

Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal[J]. J Nucl Med, 2008, 49(5):764-770.

[9]

Zanotti-Fregonara P, Hindié E, Toubert ME, et al. What role for recombinant human TSH in the treatment of metastatic thyroid cancer?[J]. Eur J Nucl Med Mol Imaging, 2009, 36(6):883-885. doi: 10.1007/s00259-008-1046-0

[10]

Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma:a comprehensive review[J]. Endocr Relat Cancer, 2005, 12(1):49-64. doi: 10.1677/erc.1.00830

[11]

Rosário PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with ¹³¹I is associated with lowered radiotoxicity[J]. J Nucl Med, 2008, 49(11):1776-1782. doi: 10.2967/jnumed.108.050591

[12]

Frigo A, Dardano A, Danese E, et al. Chromosome translocation frequency after radioiodine thyroid remnant ablation:a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal[J]. J Clin Endocrinol Metab, 2009, 94(9):3472-3476. doi: 10.1210/jc.2008-2830

[13]

Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer:effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation[J]. J Clin Endocrinol Metab, 2003, 88(9):4110-4115. doi: 10.1210/jc.2003-030298

[14]

Rosario PW, Mineiro FA, Lacerda RX, et al. Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine[J]. Thyroid, 2012, 22(3):332-333. doi: 10.1089/thy.2011.0242

[15]

Barbaro D, Boni G, Meucci G, et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants[J]. Nucl Med Commun, 2006, 27(8):627-632. doi: 10.1097/00006231-200608000-00005

[16]

Taieb D, Sebag F, Cherenko M, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation(RRA)with recombinant human TSH(rhTSH):a randomized controlled study[J]. Clin Endocrinol(Oxf), 2009, 71(1):115-123. doi: 10.1111/j.1365-2265.2008.03424.x

[17]

Molinaro E, Giani C, Agate L, et al. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up[J]. J Clin Endocrinol Metab, 2013, 98(7):2693-2700. doi: 10.1210/jc.2012-4137

[18]

Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2008, 35(10):1941-1959. doi: 10.1007/s00259-008-0883-1

[19]

American Thyroid Association(ATA)Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214. doi: 10.1089/thy.2009.0110

[20]

傅宏亮, 杜学亮, 顾振辉, 等.腺叶切除不完全分化型甲状腺癌¹³¹I疗效观察[J].上海交通大学学报:医学版, 2010, 30(3):268-270.

[21]

Bal CS, Kumar A, Pant GS. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer[J]. Nucl Med Commun, 2003, 24(2):203-208. doi: 10.1097/00006231-200302000-00013

[22]

Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23 Suppl 7:S110-119.

[23]

Bal CS, Kumar A, Chandra P, et al. A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy[J]. Acta Oncol, 2006, 45(8):1067-1072. doi: 10.1080/02841860500418377

[24]

Santra A, Bal S, Mahargan S, et al. Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer[J]. Nucl Med Commun, 2011, 32(1):52-58. doi: 10.1097/MNM.0b013e328340e74c

[25]

Randolph GW, Daniels GH. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid[J]. Thyroid, 2002, 12(11):989-996. doi: 10.1089/105072502320908321

[26]

Giovanella L, Piccardo A, Paone G, et al. Thyroid lobe ablation with iodine-131 in patients with differentiated thyroid carcinoma:a randomized comparison between 1.1 and 3.7 GBq activities[J]. Nucl Med Commun, 2013, 34(8):767-770. doi: 10.1097/MNM.0b013e3283622f3d

[27]

Barbesino G, Goldfarb M, Parangi S, et al. Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma:long-term follow-up[J]. Thyroid, 2012, 22(4):369-376. doi: 10.1089/thy.2011.0198

[28]

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: thyroid carcinoma[EB/OL]. [2013-06-06]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

[29]

Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2010, 21(5):214-219.

[30]

董峰, 周荫保.分化型甲状腺癌术后¹³¹I清甲效果的影响因素[J].国际放射医学核医学杂志, 2010, 34(1):27-31. doi: 10.3760/cma.j.issn.1673-4114.2010.01.007

[31]

Cheng W, Ma C, Fu H, et al. Low-or hgh-dse rdioiodine rmnant alation for dfferentiated tyroid crcinoma:a meta-analysis[J]. J Clin Endocrinol Metab, 2013, 98(4):1353-1360. doi: 10.1210/jc.2012-3682

[32]

Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5):418-428. doi: 10.1016/0002-9343(94)90321-2

[33]

Creutzig H. High or low dose radioiodine ablation of thyroid remnants?[J]. Eur J Nucl Med, 1987, 12(10):500-502. doi: 10.1007/BF00620474

[34]

Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer[J]. J Nucl Med, 1991, 32(2):252-254.

[35]

Bal C, Padhy AK, Jana S, et al. Prospective randomized clinical trial to evaluate the optimal dose of ¹³¹I for remnant ablation in patients with differentiated thyroid carcinoma[J]. Cancer, 1996, 77(12):2574-2580. doi: 10.1002/(SICI)1097-0142(19960615)77:12<2574::AID-CNCR22>3.0.CO;2-O

[36]

Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma:a randomized clinical trial in 509 patients[J]. J Clin Endocrinol Metab, 2004, 89(4):1666-1673. doi: 10.1210/jc.2003-031152

[37]

Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer[J]. N Engl J Med, 2012, 366(18):1674-1685. doi: 10.1056/NEJMoa1109589

[38]

Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J]. N Engl J Med, 2012, 366(18):1663-1673. doi: 10.1056/NEJMoa1108586

[39]

Maenpaa HO, Heikkonen J, Vaalavirta L, et al. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study[J/OL]. PLoS One, 2008, 3(4): 1885[2013-06-06]. http://www.ncbi.nlm.nih.gov/pubmed/18382668.

[40]

DoiSA, Woodhouse NJ, Thalib L, et al. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer:a meta-analysis revisited[J]. Clin Med Res, 2007, 5(2):87-90. doi: 10.3121/cmr.2007.763

[41]

Fallahi B, Beiki D, Takavar A, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma:a large randomized clinical trial[J]. Nucl Med Commun, 2012, 33(3):275-282. doi: 10.1097/MNM.0b013e32834e306a